Duration of Stable Disease Is Associated with Overall Survival in Patients with Advanced Hepatocellular Carcinoma Treated with Sorafenib

Tadaaki Arizumi; Kazuomi Ueshima; Hirokazu Chishina; Masashi Kono; Mashiro Takita; Satoshi Kitai; Tatsuo Inoue; Norihisa Yada; Satoru Hagiwara; Yasunori Minami; Toshiharu Sakurai; Naoshi Nishida; Masatoshi Kudo

doi:10.1159/000368006

Related publications

Article2018

Predictor factor of survival in advanced hepatocellular carcinoma treated with sorafenib ∼a multicenter study∼

Chikara Ogawa, Masahiro Morita, Akina Omura, Mitsushige Shibatoge, Akemi Tsutsui, Tomonori Senoh, Takuya Nagano, Kouichi Takaguchi, Joji Tani, Asahiro Morishita, Hirohito Yoneyama, Tsutomu Masaki, Akio Moriya, Masaharu Ando, Akihiro Deguchi, Masatoshi Kudo

Article2018

KEYNOTE-224: Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib.

Andrew X. Zhu, Richard S. Finn, Stéphane Cattan, Julien Edeline, Sadahisa Ogasawara, Daniel H. Palmer, Chris Verslype, Vittorina Zagonel, Olivier Rosmorduc, Arndt Vogel, Debashis Sarker, Gontran Verset, Stephen L. Chan, Jennifer J. Knox, Bruno Daniele, Scot Ebbinghaus, Junshui Ma, Abby B. Siegel, Ann‐Lii Cheng, Masatoshi Kudo

Dataset

Supplementary Material for: Objective Response by mRECIST Is an Independent Prognostic Factor for Overall Survival in Hepatocellular Carcinoma Treated with Sorafenib in the SILIUS Trial

Masatoshi Kudo, Kazuomi Ueshima, Yasutaka Chiba, Sadahisa Ogasawara, Shuntaro Obi, Namiki Izumi, Hiroshi Aikata, Hiroaki Nagano, Etsuro Hatano, Yasuharu Sasaki, Keisuke Hino, Takashi Kumada, Kazuhiro Yamamoto, Yoichi Imai, Shouta Iwadou, Chikara Ogawa, Takuji Okusaka, Fumihiko Kanai, Yasuaki Arai

Article2020

Objective response (OR) by mRECIST to predict overall survival (OS) in patients with hepatocellular carcinoma (HCC) treated with sorafenib in the SILIUS trial.

Masatoshi Kudo, Kazuomi Ueshima, Chikara Ogawa, Yasutaka Chiba

Article2024

Nivolumab plus ipilimumab combination therapy in patients with advanced hepatocellular carcinoma previously treated with sorafenib: 5-year results from CheckMate 040

Ignacio Melero, Thomas Yau, Yoon‐Koo Kang, T.-Y. Kim, Armando Santoro, B. Sangro, Masatoshi Kudo, Ming Hou, Ana Matilla, Francesco Tovoli, Jennifer J. Knox, Aiwu Ruth He, Bassel F. El‐Rayes, M. Acosta-Rivera, Ho Yeong Lim, S. Soleymani, J. Yao, Jaclyn Neely, M. Tschaika, Chiun Hsu, Anthony B. El-Khoueiry